VEC.L - Vectura Group plc

LSE - LSE Delayed price. Currency in GBp
78.85
-3.25 (-3.96%)
As of 3:00PM BST. Market open.
Stock chart is not supported by your current browser
Previous close82.10
Open82.00
Bid78.85 x 382500
Ask79.00 x 252100
Day's range77.40 - 82.00
52-week range68.00 - 151.50
Volume5,238,225
Avg. volume6,832,911
Market cap522.102M
Beta0.45
PE ratio (TTM)N/A
EPS (TTM)-12.60
Earnings date19 Mar 2018 - 23 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est135.73
  • Reuterslast month

    Vectura posts wider 2017 loss, revenue rise

    The company, which bought rival SkyePharma for 441 million pounds in June 2016, said pretax loss stood at 102.2 million pounds against analysts' expectations of a loss of 88.7 million pounds, according to Thomson Reuters data. The asthma inhaler-maker said total royalties fell to 52.6 million pounds from 74.5 million pounds a year earlier. The company derives 35 percent of its revenue from royalties.

  • Two defensive growth stocks I’d buy and hold for 10 years
    Fool.co.uklast month

    Two defensive growth stocks I’d buy and hold for 10 years

    These two stocks are struggling today but the future could still be bright.

  • Reuters - UK Focuslast month

    BUZZ-Hikma, Vectura: Shares down, generic Advair delayed again

    ** Shares of Hikma Pharmaceutical fall 6 pct at open, now down 2 pct, with Vectura down 5.3 pct ** Hikma fails to find quick resolution in dispute with U.S. FDA over plans to launch a generic copy of GlaxoSmithKline's ...

  • Reuterslast month

    GSK wins new reprieve as Hikma's generic Advair delayed again

    The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.

  • Reuters - UK Focuslast month

    GSK wins new reprieve as Hikma's generic Advair delayed again

    GlaxoSmithKline (Other OTC: GLAXF - news) has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura, said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well.

  • Reuters2 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters - UK Focus2 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline (Other OTC: GLAXF - news) has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters - UK Focus5 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time. The dispute between the Jordan-based firm, its partner Vectura and the U.S FDA delays any eventual approval of the generic version of the drug. Shares (Berlin: DI6.BE - news) of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters5 months ago

    Hikma, Vectura in dispute with FDA over generic Advair

    LONDON (Reuters) - Hikma (HIK.L) and its partner Vectura (VEC.L) are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's (GSK.L) popular lung ...

  • Reuters - UK Focus7 months ago

    Vectura asthma inhaler makes "positive" regulatory progress in Europe

    Oct (Shenzhen: 000069.SZ - news) 4 (Reuters) - British drugmaker Vectura said its asthma inhaler Flutiform had made favourable regulatory progress in Europe, and it can now apply for approvals through its partner. Vectura said its partner Mundipharma confirmed a "successful outcome" for the inhaler, when first assessed by the UK medicines and healthcare products regulatory agency -- which covers 18 countries across Europe. "This positive DCP outcome is an important step in the regulatory process and Mundipharma can now begin to apply for national approvals and reimbursement in the European countries covered by this procedure", Chief Executive Officer James Ward-Lilley said in a statement on Wednesday.

  • Reuters - UK Focus8 months ago

    Drugmaker Vectura warns of destocking hit, shares slide

    British drugmaker Vectura reported a doubling in first-half losses and warned full-year revenues would be hit by customers running down stocks of asthma inhaler Flutiform, sending its shares as much as 14 percent lower on Wednesday. The company, which bought rival SkyePharma (LSE: 4547152.L - news) for 441 million pounds ($575 million) in June 2016, said full-year revenues from product supplies and device sales were likely to be flat on a comparable basis with the previous year. "Although Vectura has undertaken to lower its R&D expense to compensate such that the net effect is 'broadly neutral at earnings,' we think the market may be disappointed by the implied negative change to 2017 earnings mix," they wrote in a research note, keeping a "hold" rating on the stock.

  • Reuters - UK Focus8 months ago

    Drugmaker Vectura's H1 revenue up 6 pct on rising sales of inhaled products

    Sept 6 - Vectura said revenue rose 6 percent in the first half of the year, driven by rising sales of its recently launched inhaled products and the continued weakness of sterling against a basket of its ...

  • Reuters - UK Focus11 months ago

    GSK escapes Advair hit for now as second generic bid fails

    GlaxoSmithKline (Other OTC: GLAXF - news) is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators. Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) said on Thursday the Food and Drug Administration (FDA) had decided not to approve its version of the inhaled treatment for asthma and chronic lung disease at this time, due to "major" issues with the application. Hikma and its partner Vectura are in a race with Mylan to launch the first U.S. generic copy of Advair that can be substituted for the original product in pharmacies.

  • Reuters - UK Focus11 months ago

    BUZZ-Hikma: bottom of STOXX as generic Advair faces US delay, 2017 approval unlikely

    ** Drugmaker Hikma down 8 pct, bottom of Stoxx 600 , with its partner Vectura -9% ** Hikma says US regulators have decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair ...

  • Reuters - UK Focus11 months ago

    Hikma's generic Advair faces U.S. delay, 2017 approval unlikely

    Hikma Pharmaceuticals said on Thursday that U.S. regulators had decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair at this time, due to 'major' issues with its application. ...

  • Reuters - UK Focus11 months ago

    BUZZ-Hikma: down on speculation of FDA 'no' for generic Advair

    ** Shares in Hikma Pharmaceuticals and its partner Vectura down 1.6% and 2.3% on speculation U.S. regulators won't grant immediate approval for generic version of GlaxoSmithKline's blockbuster inhaled ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes